Debiopharm International S.A.
USPTO PatentsView assignee record - 16 granted patents across 11 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Debiopharm ranks #17,592 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 11 technology areas.
- #17,592
- of 49,997 US assignees by volume
- Top 39%
- by Innovation Score (39.2/100)
- 20.3
- avg claims per patent
- +233%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R17592 · Foreign Corporation #17,592 · 16 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL
- GRANTS-MICRO 16 grants
- MID-PACK #17,592/49,997
- PHOTO-FINISH DataWalk Spólka…
- CPC-FOCUS A61P · 11 areas
- INNOV-THIN 39.2/100
- CLAIMS-DENSE 20.3 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-SURGE +233% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: DataWalk Spólka Akcyjna (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Debiopharm’s 39.2 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Debiopharm
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Debiopharm Internati… · this assignee
Debiopharm Internati… · this assignee
39 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Debiopharm's Innovation Score is 39.2/100 (top 39% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Debiopharm?
Each dot is one of Debiopharm’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Debiopharm’s own 20.3 claims/patent is ABOVE the 13.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Debiopharm's grants concentrate
Debiopharm International S.A. is a focused PatentsView assignee: 11 CPC subclasses with 87.5% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (4 grants) versus a trough of 1 in 2019. By volume, Debiopharm sits between DSS Pure Air, Inc. and Descript, Inc..
Debiopharm's three-year grant acceleration
Debiopharm International S.A. shows 5 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Debiopharm's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- DSS Pure Air
DSS Pure Air, Inc.
16 patents
- Datawalk Spólka A…
DataWalk Spólka Akcyjna
16 patents
- David Clark Incor…
David Clark Company Incorporated
16 patents
- De Ruiter Intelle…
De Ruiter Intellectual Property B.V.
16 patents
- Decopac
Decopac, Inc.
16 patents
- Deep Vision
Deep Vision Inc.
16 patents
- Delkor Systems
Delkor Systems, Inc.
16 patents
- Descript
Descript, Inc.
16 patents
- Debiopharm Intern… ◀
Debiopharm International S.A.
16 patents
What this shows Debiopharm holds 16 patents at rank #17,603, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Debiopharm
By rank, the assignees closest to #17,603 in granted patent volume.
- DSS Pure Air, Inc. #17,599 · 16 patents
- DataWalk Spólka Akcyjna #17,600 · 16 patents
- David Clark Company Incorporated #17,601 · 16 patents
- De Ruiter Intellectual Property B.V. #17,602 · 16 patents
- Decopac, Inc. #17,604 · 16 patents
- Deep Vision Inc. #17,605 · 16 patents
- Delkor Systems, Inc. #17,606 · 16 patents
- Descript, Inc. #17,607 · 16 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Debiopharm's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Debiopharm's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
39 Top 39% higher than 61% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 2 | 12.5% |
| 2019 | 1 | 6.3% |
| 2020 | 4 | 25.0% |
| 2021 | 1 | 6.3% |
| 2022 | 3 | 18.8% |
| 2023 | 1 | 6.3% |
| 2024 | 1 | 6.3% |
| 2025partial year | 3 | 18.8% |
Which technologies does Debiopharm International S.A. patent most?
Top 11 of 11 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Debiopharm International S.A.'s patent record in context - here's where to go next.
- Debiopharm International S.A.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 87.5% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #17,592 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Debiopharm International S.A. against DSS Pure Air, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 39.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.